Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Esophageal Squamous Cell Carcinoma × Ramucirumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 36 Carcinoma, Non-Small-Cell Lung 30 Neoplasms 10 Neoplasm Metastasis 9 Lung Neoplasms 9 Adenocarcinoma 9 Colorectal Neoplasms 8 Esophageal Neoplasms 7 Carcinoma, Hepatocellular 7 Colonic Neoplasms 5 Carcinoma, Renal Cell 5 Breast Neoplasms 5 Adenocarcinoma Of Esophagus 4 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Rectal Neoplasms 3 Melanoma 3 Liver Neoplasms 3 Carcinoma, Transitional Cell 3 Biliary Tract Neoplasms 3 Ureteral Neoplasms 2 Thymoma 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Sarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Non-small Cell Lung Cancer Metastatic 2 Malignant Solid Tumor 2

Interventions

Cisplatin 101 Radiotherapy 76 Paclitaxel 67 Fluorouracil 54 Drug Therapy 36 Carboplatin 36 Irinotecan 29 pembrolizumab 26 Docetaxel 23 tislelizumab 21 Oxaliplatin 21 Neoadjuvant Therapy 21 toripalimab 20 Radiation 18 sintilimab 16 camrelizumab 16 Surgical Procedures, Operative 15 Nivolumab 15 Esophagectomy 15 Leucovorin 14 Cetuximab 14 Capecitabine 14 130-nm albumin-bound paclitaxel 14 nimotuzumab 11 TP protocol 11 S 1 (combination) 11 apatinib 10 Radiotherapy, Intensity-Modulated 10 Albumin-Bound Paclitaxel 9 nedaplatin 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03762564 2022-12-08

RAMOS

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡